54 completed, 25 unknown, 21 recruiting, 17 not yet recruiting. 50 Phase 2, 49 Phase 1, 17 Not applicable, 14 Phase 3, 4 Early Phase 1.
Follow Hematological Malignancies: new trials by email Literature Review of Hematological Malignancies trials Research Report on Hematological Malignancies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies C9/CD5CAR/IL-15 NK cells, Rituximab, Fludarabine - Hematological Malignancies | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 70 | 2027-02-28 | 2026-08-20 |
| Immunological Impact of a Post Cell Therapy Treatment With FLT3 Inhibitors Gilteritinib - Hematological Malignancies | Not applicable | Not yet recruiting | Centre Hospitalier Universitaire de Nice | 10 | 2026-09-01 | 2026-06-22 |
| A Phase I, Single-Arm, Open-Label Clinical Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of CHT101 Injection in Subjects With Relapsed/Refractory T-Cell and B-Cell Hematological Malignancies CD70-targeted chimeric antigen receptor allogeneic T-cell injection (CHT101) - Hematological Malignancies | Phase 1 | Not yet recruiting | Nanjing Miracle Biotechnology Co., Ltd. | 30 | 2026-09-01 | 2026-09-09 |
| A Clinical Study to Evaluate CHT101 Injection in Subjects With Relapsed/Refractory T-Cell and B-Cell Hematologic Malignancies CHT101 - Hematological Malignancies | Phase 1 | Not yet recruiting | Nanjing Miracle Biotechnology Co., Ltd. | 30 | 2026-09-01 | 2026-09-09 |
| M-2018-334 in Hematological Malignancies CliniMACS Prodigy® LP-TCRα/β-19-45RA (Trial Version) - Hematological Malignancies | Not applicable | Recruiting | Miltenyi Biomedicine GmbH | 18 | 2026-08-21 | 2026-09-11 |
| mNGS for IFD in Patients With Hematological Malignancies metagenomic next-generation sequencing - Hematological Malignancies, Invasive Fungal Disease | Not yet recruiting | Nanfang Hospital, Southern Medical University | 50 | 2026-08-10 | 2026-08-13 | |
| Risk Prediction Scores for Cardiotoxicity in Cancer Patients Treated With Cardiotoxic Anticancer Therapies in Europe antineoplastic agents, endocrine therapy, immunostimulants drugs (ATC classification) - Cancer, Anticancer Treatment | Not yet recruiting | University Hospital, Caen | 10000 | 2026-06-22 | 2026-07-22 | |
| Luspatercept vs Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies Luspatercept, Epoetin - Luspatercept, Epoetin | Phase 2 / Phase 3 | Not yet recruiting | Nanfang Hospital, Southern Medical University | 90 | 2026-06-15 | 2026-06-09 |
| Complementary and Alternative Medicine Among Patients With Hematologic Malignancies in France Questionnaire on Complementary and Alternative Medicines (CAM) - Hematological Malignancies | Not applicable | Not yet recruiting | University Hospital, Limoges | 85 | 2026-06-15 | 2026-04-21 |
| Acalabrutinib Maleate and Bortezomib for Patients With HLA Antibodies Acalabrutinib maleate, bortezomib, HLA-matched or crossmatched irradiated platelets - Hematological Malignancies, Platelet Transfusion Refractoriness (PTR) | Phase 3 | Not yet recruiting | The First Affiliated Hospital of Soochow University | 42 | 2026-06-01 | 2026-06-09 |
| Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis Luspatercept, Control - Luspatercept, Poor Erythroid Engraftment | Phase 2 / Phase 3 | Not yet recruiting | Nanfang Hospital, Southern Medical University | 196 | 2026-05-01 | 2026-04-20 |
| Exploratory Study on the Treatment of Recurrent and Refractory Hematological Malignancies With WGb-0302 Injection WGb-0302 injection - Hematological Malignancies | Early Phase 1 | Not yet recruiting | Sichuan University | 20 | 2026-02-01 | 2026-01-23 |
| Exploratory Study on in Vivo CAR-T Therapy Targeting CD20 for the Treatment of Hematological Malignancies In vivo CAR-T drug targeting CD20 based on mRNA-LNP - Hematological Malignancies | Early Phase 1 | Not yet recruiting | The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army | 47 | 2026-01-26 | 2026-01-23 |
| A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies DS3790a, Combination drug - Hematological Malignancies, B-cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | Daiichi Sankyo | 420 | 2026-01-16 | 2026-08-24 |
| Prospective Study Evaluate the Timing of Empirical Treatment for Carbapenem-resistant Bacterials (CROEAT Study) Empirical treatment - Carbapenem-resistant Enterobacterales, Neutropenia | Not applicable | Not yet recruiting | Shanghai Jiao Tong University School of Medicine | 91 | 2025-08-01 | 2025-07-02 |
| 18F-Pentixafor PET in Hematologic Malignancies 18F-Pentixafor - Hematological Malignancies | Recruiting | First Affiliated Hospital of Zhejiang University | 100 | 2025-07-01 | 2025-08-14 | |
| Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation Attenuated-dose Cyclophosphamide, High-dose Cyclophosphamide, Sirolimus - Hematological Malignancies, Graft-versus-Host Disease (GVHD) | Phase 2 | Recruiting | University of Nebraska | 126 | 2025-06-23 | 2026-10-09 |
| Observational Study for the Evaluation of Immune-mediated Endocrinological Adverse Events in Patients With Hematological Malignancies and Subjected to Treatment With Immune-checkpoint Inhibitors Hematological Malignancies | Recruiting | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 100 | 2025-06-01 | 2025-02-28 | |
| Feasibility of the Use of Weighted Blankets to Improve Sleep Among Patients With Hematological Malignancies Weighted Blanket - Hematological Malignancies | Not applicable | Active not recruiting | M.D. Anderson Cancer Center | 20 | 2025-05-01 | 2026-08-10 |
| To Study Lower Dose of Cyclophosphamide After Stem Cell Transplant for Blood Cancers Cyclophosphamide - Haploidentical Hematopoietic Stem Cell Transplant, Hematological Malignancies | Phase 2 | Recruiting | Tata Memorial Centre | 20 | 2025-03-26 | 2026-07-22 |
Showing 20 of 139. Sign in to see all of them.
Hematologic Neoplasms (139) · Lymphoma (13) · Multiple Myeloma (13) · Leukemia (11) · Graft vs Host Disease (9) · Neoplasms (9) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (9) · Leukemia, Myeloid, Acute (7) · Myelodysplastic Syndromes (7) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (6) · Hodgkin Disease (5) · Leukemia, Lymphocytic, Chronic, B-Cell (5) · Lymphoma, Non-Hodgkin (5) · Neutropenia (5) · COVID-19 (3)
Hemic and Lymphatic Diseases (139) · Neoplasms by Site (139) · Hematologic Diseases (136) · Neoplasms (130) · Immune System Diseases (35) · Neoplasms by Histologic Type (27) · Immunoproliferative Disorders (25) · Lymphoproliferative Disorders (25) · Lymphatic Diseases (24) · Pathological Conditions, Signs and Symptoms (23) · Pathologic Processes (20) · Disease Attributes (16) · Cardiovascular Diseases (15) · Vascular Diseases (15) · Blood Protein Disorders (14)
Cyclophosphamide (7) · Mycophenolic Acid (6) · fludarabine (6) · Antilymphocyte Serum (4) · Rituximab (3) · Sirolimus (3) · Stem Cell Transplantation (3) · Tacrolimus (3) · Busulfan (2) · Hematopoietic Stem Cell Transplantation (2) · Whole-Body Irradiation (2) · belinostat (2) · fludarabine phosphate (2) · luspatercept (2) · talquetamab (2)
M.D. Anderson Cancer Center (6) · Nanfang Hospital, Southern Medical University (5) · Assistance Publique - Hôpitaux de Paris (4) · Janssen Research & Development, LLC (4) · University of Liege (4) · Gamida Cell ltd (3) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (3) · Zhejiang University (3) · Acrotech Biopharma Inc. (2) · AstraZeneca (2) · Azienda Ospedaliera San Giovanni Battista (2) · Centre Hospitalier Universitaire de Besancon (2) · Centre Hospitalier Universitaire de Nice (2) · Dana-Farber Cancer Institute (2) · First Affiliated Hospital of Zhejiang University (2)
United States (50) · China (27) · France (23) · Italy (20) · Netherlands (12) · Spain (12) · Germany (11) · Belgium (9) · Israel (6) · United Kingdom (6) · Canada (5) · Australia (4) · Poland (4) · Sweden (4) · Denmark (3)
Mitchell Horwitz, MD (4) · Frederic Baron, MD, PhD (3) · Qifa Liu (3) · Yves Beguin, MD, PhD (3) · Francesco Passamonti, MD (2) · Harry Schouten, MD (2) · Neal Flomenberg, MD (2) · Amin Alousi, MD (1) · Ana G. Antun, MD, MSc (1) · Andrea Velardi, Prof (1) · Anthony Sung, MD (1) · Arnon Nagler, MD (1)
PMID 35661166, PMID 36991547, PMID 37132225, PMID 37713090, PMID 37960969, PMID 38052709, PMID 38110653, PMID 39155155, PMID 39172760, PMID 40090350, PMID 40332715, PMID 40631904, PMID 40864183, PMID 41313549, PMID 41485109, PMID 41886220, PMID 42299486, PMID 42561120, PMID 42669079, PMID 42803498, PMID 11013273, PMID 11719388, PMID 11939602, PMID 11985515, PMID 12171484, PMID 12692611, PMID 13411920, PMID 14113077, PMID 15064010, PMID 15110092, PMID 15602019, PMID 16616780, PMID 1671578, PMID 17507164, PMID 18489989, PMID 18500368, PMID 19088047, PMID 19203728, PMID 19345145, PMID 19473094, PMID 19786984, PMID 20060484, PMID 20109568, PMID 20410061, PMID 20424252, PMID 2143514, PMID 21460603, PMID 21565903, PMID 22147646, PMID 22863841
2023 (6), 2017 (3), 2016 (2), 2005 (1), 2015 (1), 2018 (1), 2025 (1)